Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.2. Drivers
4.2.1. Growing age-related eye diseases across the world, growing aged population
4.2.2. Advancements in technology
4.2.3. The introduction of new products for the treatment of age-related macular degeneration (AMD)

4.3. Restraints
4.3.1. Availability of alternative treatment options
4.3.2. High cost of treatments
4.4. Opportunities
4.5. Impact Analysis
5. Industry Factors
5.1. Porter’s Five Forces
5.2. Regulator Analysis
5.3. Supply Chain Analysis
5.4. Reimbursement Analysis
5.5. Pipeline analysis
5.6. Pricing Analysis
5.7. Unmet Needs
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Lucentis*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Eylea
7.4. Avastin
7.5. Others
8. By Disease Type
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
8.1.2. Market Attractiveness Index, By Disease Type
8.2. Dry AMD*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Wet AMD
9. By Treatment Type
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
9.1.2. Market Attractiveness Index, By Treatment Type
9.2. Injecting Anti-vascular endothelial growth factor*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Photodynamic therapy
9.4. Laser surgery
9.5. Antibiotic drops
9.6. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. The U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. South America
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Brazil
10.3.6.2. Argentina
10.3.6.3. Rest of South America
10.4. Europe
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Germany
10.4.6.2. The U.K.
10.4.6.3. France
10.4.6.4. Spain
10.4.6.5. Italy
10.4.6.6. Rest of Europe
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East & Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Novartis
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Bayer
12.3. Roche
12.4. Bausch & Lomb
12.5. Allergan
12.6. Iconic Therapeutics
12.7. Neurotech Pharmaceuticals
12.8. Regeneron Pharmaceuticals Inc
12.9. Alcon
12.10 Santen Pharmaceutical
LIST NOT EXHAUSTIVE
13. Global Age-Related Macular Degeneration Market – DataM
13.1. Appendix
13.2. About Us
13.3. Contact Us